Table 5.

Univariate and multivariate analysis of biochemical non-evidence of disease rate

		Univariate		Multivariate
Variant		P-value	HR	P-value	HR
Hormonal therapy	No vs Yes	0.132	2.953
Damico risk criteria	Low vs Intermediate	0.429	1.526
Age	≤70 vs >70	0.931	0.958
Gleason score	<3 + 4 vs >4 + 3	0.071	0.368	0.206	2.065
Prostate volume (ml)	≤32 vs >32	0.617	1.285
T stage	1c vs ≥2a	0.251	3.072
Experience (patients)	<152 vs ≥153	0.267	1.744
D90 (Gy)	≤145 vs >145	0.158	2.195
Initial PSA (ng/ml)	<6 vs ≥6	0.029	0.310	0.062	2.912
Doubling time (years)	≥2 vs <2	0.890	0.921
(hormone naïve only)
	≥1 vs <1	0.489	1.448
Testosterone	≥6 vs <6	0.686	1.327
(hormone naïve only)
BMI	≤25 vs >25	0.482	0.697

PSA = prostate specific antigen, HR = hazard ratio, D90 = dose to 90% of prostate volume at 1 month.